X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock Has Average Target Price of $11.25 According to Analysts

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) has been assigned an average rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $11.25.

Several analysts have weighed in on the stock. Wells Fargo & Company began coverage on shares of X4 Pharmaceuticals in a research note on Friday, July 10th. They set an “overweight” rating and a $11.00 price objective on the stock. Weiss Ratings lowered X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, October 20th.

Insider Activity at X4 Pharmaceuticals

In other news, CFO David Kirske sold 11,767 shares of the stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $2.86, for a total value of $33,653.62. Following the transaction, the chief financial officer owned 155,983 shares of the company’s stock, valued at $446,111.38. This represents a 7.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Chairman Adam Craig sold 47,436 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $4.44, for a total value of $210,615.84. Following the completion of the transaction, the chairman directly owned 328,651 shares in the company, valued at $1,459,210.44. The trade was a 12.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 83,779 shares of company stock worth $353,387 over the last ninety days. Company insiders own 1.13% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in XFOR. Alps Advisors Inc. grew its stake in X4 Pharmaceuticals by 36.2% in the third quarter. Alps Advisors Inc. now owns 130,424 shares of the company’s stock valued at $378,000 after acquiring an additional 34,698 shares during the period. WINTON GROUP Ltd raised its position in shares of X4 Pharmaceuticals by 35.8% during the second quarter. WINTON GROUP Ltd now owns 14,400 shares of the company’s stock worth $67,000 after purchasing an additional 3,800 shares during the period. Squarepoint Ops LLC acquired a new stake in shares of X4 Pharmaceuticals during the second quarter worth about $313,000. AXQ Capital LP acquired a new stake in shares of X4 Pharmaceuticals during the second quarter worth about $107,000. Finally, Wellington Management Group LLP bought a new position in shares of X4 Pharmaceuticals during the 2nd quarter valued at about $242,000. 72.03% of the stock is currently owned by institutional investors.

X4 Pharmaceuticals Trading Up 2.2%

Shares of XFOR stock opened at $3.24 on Monday. X4 Pharmaceuticals has a 1 year low of $2.43 and a 1 year high of $4.83. The firm’s fifty day simple moving average is $3.28 and its 200 day simple moving average is $3.79. The company has a quick ratio of 11.02, a current ratio of 11.30 and a debt-to-equity ratio of 0.49.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its earnings results on Wednesday, November 4th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02. The business had revenue of $2.88 million for the quarter, compared to the consensus estimate of $2.30 million. X4 Pharmaceuticals had a negative return on equity of 63.05% and a negative net margin of 568.80%. Analysts expect that X4 Pharmaceuticals will post -0.67 earnings per share for the current fiscal year.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing therapies for rare diseases caused by disorders of the immune system. The company’s research centers on the CXCR4 pathway, which plays a role in the movement and function of immune cells.

X4’s lead product, XOLREMDI (mavorixafor), is an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration for use in patients aged 12 and older with WHIM syndrome, a rare primary immunodeficiency disorder.